New Data On Investigational Agent TMC278 In Anitretroviral-Naive HIV Patients

... Tibotec Pharmaceuticals Ltd. presented the first results of the phase 2b dose-finding study of TMC278 at the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles earlier this week. TMC278 is a next-generation investigational non- nucleoside reverse transcriptase inhibitor (NNRTI). It is currently being studied in treatment-naive HIV patients in phase 2. [click link for full article] ...